scholarly journals QUANTIFICATION OF EXERCISE TOLERANCE IN CONGESTIVE HEART FAILURE AND ROLE OF ACE INHIBITORS

1998 ◽  
Vol 54 (4) ◽  
pp. 331-334
Author(s):  
PK HASIJA ◽  
SD KARLOOPIA ◽  
BN SHAHI ◽  
SS CHAUHAN
1990 ◽  
Vol 3 (5) ◽  
pp. 318-331
Author(s):  
Mark A. Munger ◽  
Stephanie F. Gardner ◽  
Robert C. Jarvis

The angiotensin-converting enzyme (ACE) inhibitors represent the gold standard of vasodilator therapy for congestive heart failure through blunting of the endocrinologic manifestations of heart failure. The future role of these agents may be in the asymptomatic and mild stages of heart failure. ACE inhibitors have been shown to decrease morbidity and mortality with the natural history of this disease being altered. The future will bring many new ACE inhibitors to market, with the challenge for physicians and pharmacists to understand the important distinctions of each specific agent. © 1990 by W.B. Saunders Company.


1996 ◽  
Vol 1 (3) ◽  
pp. 259-264
Author(s):  
Peter Ott ◽  
Frank I. Marcus

It is now well established that digoxin is an effective drug for the treatment of heart failure. Since treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality in congestive heart failure, digoxin should be added to ACE inhibitors in patients with moderate or severe heart failure. The beneficial effects of digoxin may be due, in part, to its well-documented sympathoinhibitory effects that can avert the adverse effects of long-term excessive sympathetic adrenergic stimulation in heart failure.


2014 ◽  
Vol 186 (2) ◽  
pp. 496
Author(s):  
P.J. Speicher ◽  
A.M. Ganapathi ◽  
B.R. Englum ◽  
S.N. Vaslef

Sign in / Sign up

Export Citation Format

Share Document